Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 14,901–15,000 of 15,747
Self-amplifying mRNA expression is governed by mitochondrial machinery and ACSL4Preprint
Tshering, L. F., Wang, C., Xiang, Q., Kundu, S., Solórzano, A., Chaparro‐Riggers, J. F., Lin, L., & Paksa, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.13.659366
Insights into the management of anorectal disease in the coronavirus 2019 disease era
Amjad, W., Haider, R., Malik, A., & Qureshi, W. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211028117 · Cited by 1
van der Goes, T. I. F. (2021) · Revista de la Facultad de Medicina UNAM · doi:10.22201/fm.24484865e.2021.64.1.01
Haddad, S. F., Zurlo, J. J., Wang, Z., Richards, B., Badjatia, N., & Coppock, D. (2022) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000001202
Rice, A., Verma, M., Voigt, E. A., Battisti, P., Beaver, S., Reed, S., Dinkins, K., Mody, S., Zakin, L., Tanaka, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.29.470440
Nanomedicine’s Role in the COVID-19 Vaccine Development and Optimization
Kumar, J., Malhotra, J., Yadav, A. S., & Bhati, A. S. (2024) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-72467-1_3
Ruiz-Saez, H., Íñiguez, A. E., González‐Osorio, Y., Trigo-López, J., Sierra, Á., García, A. R., Planchuelo‐Gómez, Á., González-Celestino, A., Hurtado, M. L., Sierra, L., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13122900
“Our findings present an additional reason for recommending vaccination to prevent COVID-19 while also considering the reported decrease in the mortality and severity of COVID-19 [11–13].”
Bioresponsive Nanomaterials for CNS Disease
Kudryashev, J. A., Madias, M. I., & Kwon, E. J. (2022) · Springer eBooks · doi:10.1007/978-3-031-11409-0_5
SARS-CoV-2 infection in lung transplant recipients: a single-center retrospective study in Japan
Kohno, M., Ohsumi, A., Kimura, J., et al. (2025) · Surgery Today · doi:10.1007/s00595-025-03136-5
“Vaccination has been widely demonstrated to be effective for preventing COVID-19 and reducing its severity in the general population [32, 33].”
Distinct Innate Immune Responses Following Inoculation With a Replicon mRNA COVID‐19 Vaccine
Nakayama, T., Ito, T., & Katayama, K. (2026) · Microbiology and Immunology · doi:10.1111/1348-0421.70068
Post COVID-19 - Effects on Human Health
Padilla-Raygoza, N. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.105656 · Cited by 1
Dosis única de la vacuna SARS-CoV-2 m-ARN en personas mayores post-COVID-19
Colino, S. N., Abasolo, F. J. C., & Hernández, J. M. (2021) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2021.05.009
Research progress on the neutralizing antibody response to SARS-CoV-2
Teng, S., & Qu, X. (2023) · Scientia Sinica Vitae · doi:10.1360/ssv-2023-0084 · Cited by 2
Lockdown Fatigue in Pediatric Respiratory Patients: Lessons from the First COVID-19 Year
Cahal, M., Amirav, I., Rochman, M., Be’er, M., Besor, O., & Lavie, M. (2022) · Children · doi:10.3390/children9121862
“Despite the cautious optimism about the initiation of worldwide vaccinations against COVID-19 [24] and the promising results already observed in Israel [25], the COVID-19 pandemic and, accordingly, repeated lockdowns will apparently constitute the reality in the foreseeable future, especially since new COVID-19 mutati…”
ResultSafety of Aircrew and Airline Passengers During the COVID-19 Pandemic: A Narrative Review
Minoretti, P. (2024) · journal australiasian society aerospace medicine · doi:10.2478/asam-2024-0006
Bartuzi, Z., Rosada, T., Ukleja-Sokołowska, N., Napiórkowska-Baran, K., Lis, K., Żbikowska-Götz, M., Kowalczyk, W., Szynkiewicz, E., Alska, E., & Cała, Ł. (2022) · Advances in Dermatology and Allergology · doi:10.5114/ada.2022.120884 · Cited by 1
McEvoy, R., Hervol, J. R., Zhang, Y.-K., Wagner, E., Lindaas, A., Jiao, Y., Xu, S., Weintraub, E., Qian, L., Hong, V., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128460
Muriel-Granda, G., Aguirre-Iñiguez, J., Segovia, K. F. E., et al. (2024) · Communications in computer and information science · doi:10.1007/978-3-031-58950-8_24
Janžič, U., Janžič, A., Agbarya, A., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12030535
COVID-19 vaccines and their impact: An overview
Khong, K.-W., & Hung, I. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95646-8.00002-0
SARS-CoV-2 Omicron (B.1.1.529) Varyantının Virolojik, Epidemiyolojik Özellikleri ve Korunma: Derleme
Kaya, G., & Altındiş, M. (2022) · Kocaeli Üniversitesi Sağlık Bilimleri Dergisi · doi:10.30934/kusbed.1060956
Artificial intelligence can support the chemical design of multiepitope vaccine nanocarriers
Garcia-Atutxa, I., & Villanueva‐Flores, F. (2026) · Discover Chemistry. · doi:10.1007/s44371-026-00929-6 · Cited by 1
Kim, H.-Y., Bershteyn, A., Russo, R. G., McGillen, J. B., Sisti, J. S., Ko, C., Shaff, J., Newton-Dame, R., & Braithwaite, R. S. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.102904 · Cited by 1
The Impact of Vaccination on the Likelihood of COVID-19 Infection
Duong, A. H., Nguyen, G. T., Vu, H. T., Duong, L. X., Pham, H. T., & Antriyandarti, E. (2024) · Viral Immunology · doi:10.1089/vim.2024.0046 · Cited by 1
Weiner, D. B., Jansen, K. U., & Villafana, T. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00068-2
Self-citationCurrent options of covid-19 management in 2023
Stebel, R., & Husa, P. (2023) · Medicína pro praxi · doi:10.36290/med.2023.032
Liposomes and lipid nanoparticles: a tutorial for advanced chemical and structural characterisation
Minelli, C., Parot, J., Alasonati, E., Altskär, A. I., Cant, D. J. H., Counsell, J. D. P., Pan, G. D., Pont, V. D. C. D., Fernandez, Y. A. D., Doveri, L., et al. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107556
Geographically-Explicit Synthetic Populations for Agent-Based Models: A Gallery of Applications
Jiang, N., Crooks, A. T., Yin, F., & Wang, B. (2024) · Springer proceedings in complexity · doi:10.1007/978-3-031-64193-0_10 · Cited by 2
Liang, E. C., Onstad, L., Carpenter, P. A., Pergam, S. A., Flowers, M. E. D., Lee, S. J., & Liu, C. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.06.017
Adamu, H., Lawal, S., Bawa, I. A., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0277585
Who comes first: the children or the egg?
Schuster, J. E., & Howard, L. M. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(25)00183-5
A predictive model for rapid assessment of protective efficacy against emerging SARS-CoV-2 variants
Jin, L., Jia, S., Shao, C., Shen, R., Jin, P., & Li, J. (2026) · Infectious Disease Modelling · doi:10.1016/j.idm.2026.03.003 · Cited by 1
“…as well as 9 studies reporting vaccine efficacy or effectiveness against symptomatic SARS-CoV-2 infection (Baden et al., 2021; Jara et al., 2022; Logunov et al., 2021; Lumley et al., 2021; Novavax, 2021; Pearson, Magalhaes, & Deng, 2021; Polack et al., 2020; Sacks, 2021; Voysey et al., 2021).”
Som, A., & Patel, N. J. (2025) · The Journal of Rheumatology · doi:10.3899/jrheum.2025-1016
Correlação entre o autodiagnóstico de alergia alimentar e a presença de IgE específica
Eismann, F. C. P., Venturim, V. D., & Barreto, B. A. P. (2020) · Arquivos de Asmas Alergia e Imunologia · doi:10.5935/2526-5393.20200052
The Gene Sequence of the Proteins of SARS-CoV-2Preprint
Thomas, S. (2022) · Research Square · doi:10.21203/rs.3.rs-2190964/v1
Self-citationTong, T., D’Addabbo, A., Xu, J., Chalwa, H., Nguyen, A., Ochoa, P., Crispin, M., & Binley, J. Μ. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.02.543368
Evaluating the Side Effects of COVID-19 Vaccines Available in Al-Diwaniyah Province
Kazaal, M. A., Jaythoom, R. A., Mahdi, N., & Mohammed, D. (2024) · Medical Journal of Babylon · doi:10.4103/mjbl.mjbl_206_23
Improving the fidelity of uridine analog incorporation during in vitro transcriptionPreprint
Chen, T.-H., Potapov, V., Dai, N., Ong, J. L., & Roy, B. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.12.488100
Yıldız, Y., MAVİ, H. M., Sultanova, F., Büyükkörük, M., Özger, H. S., & Şenol, E. (2023) · Turkish Journal of Clinics and Laboratory · doi:10.18663/tjcl.1344632
Hoff, F. W., Goksu, S. Y., Premnath, N., Patel, P. A., Ikpefan, R., Kaur, G., Vusirikala, M., Bat, T., Chen, W., Geethakumari, P. R., et al. (2023) · Acta Medica Academica · doi:10.5644/ama2006-124.399
Malakooti, S. K., Abboud, M., Murphy, J. E., Singer, N. G., & McComsey, G. A. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.108540
(2021) · doi:10.1101/2021.12.08.21267353
“5%) previously infected) contributed 3,260 antibody measurements ≥21 days post-first dose, median (IQR) [range] 1 (1-2) [1-2] measurements per participant.”
BackgroundZou, Z., Fairley, C. K., Shen, M.-W., et al. (2021) · medRxiv · doi:10.1101/2021.07.06.21260055 · Cited by 1
“WA 1 (Scenario 9) 15/03/2020 to - State of emergency declaration; - Non-essential business closure; 5 cases 77 (18-179) cases 10 cases 25 days 1.”
BackgroundKafle, S., Chhetri, V., Bajracharya, J. L., Pokharel, L., Dawadi, S., Basnet, U., Dhungana, S., & Neupane, D. P. (2023) · medRxiv · doi:10.1101/2023.08.30.23294839
Predictors of COVID-19 Mortality: A Stratified 3 by 3 Factorial Correlation Analysis
Arori, W. O. (2026) · International Journal of Latest Technology in Engineering Management & Applied Science · doi:10.51583/ijltemas.2026.150500133
Testing for SARS-CoV-2 seroprevalence: experiences of a tertiary eye centre
Ziemssen, F., Feng, Y., Schnichels, S., Bayyoud, T., Ueffing, M., Bartz‐Schmidt, K. U., Martus, P., & Peter, A. (2021) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2020-000688
ОСОБЛИВОСТІ ФОРМУВАННЯ ІМУННОЇ ВІДПОВІДІ ПІСЛЯ ВАКЦИНАЦІЇ ВІД COVID-19
Кисельова, Г. Л., Анастасій, І. А., Тонковид, О. Б., Isaiev, V. M., Voronova, K., Шевель, І. І., Сідорова, І. В., Карпеченко, С. В., & Панченко, А. А. (2023) · Інфекційні хвороби · doi:10.11603/1681-2727.2022.4.13697
Feuchtenberger, M., Kovacs, M. S., Eder, A., Nigg, A. P., Almanzar, G., Prelog, M., & Schäfer, A. (2024) · Rheumatology Advances in Practice · doi:10.1093/rap/rkae111
Treating Earth as a living system: Facing the lacking clinical expertise
Meißner, T. (2026) · PLOS Climate · doi:10.1371/journal.pclm.0000896
Plausibility, not science, has dominated public discussions of the COVID pandemic
Risch, H. A. (2023) · American Journal of Economics and Sociology · doi:10.1111/ajes.12539
Cieślak, I., Kwapisz, M., Tronina, O., Gotlib, J., Lisik, W., Wasiak, D., Hreńczuk, M. K., Rahnama, M., & Małkowski, P. (2022) · Annals of Transplantation · doi:10.12659/aot.936949
“effective in preventing acute course of the disease [22,23].”
BackgroundMethodFluoroamphiphiles for enhancing immune response of subunit vaccine against SARS-CoV-2
Li, Y., Kang, Z., Zhang, X., Sun, Y., Han, Z., Zhang, H., Liu, Z., Liang, Y., Zhang, J., & Ren, J. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114528
Lev‐Ari, S., Rolnik, B. M., & Volovitz, I. (2021) · Biology · doi:10.3390/biology10060485
“Yet, until the development of safe and effective vaccines [21] or therapeutics, and their effective worldwide distribution, viral spread among all societies is inevitable.”
Background(2000) · Time to knit · doi:10.1016/j.ccol.2021.12.004
Development, rollout, and challenges of COVID-19 vaccines in Japan and globally
Arashiro, T., & Suzuki, T. (2021) · Uirusu · doi:10.2222/jsv.71.41
Promising Enzymes for Inhibitors Development Against COVID-19
Sun, Z., Yu, F., Qiu, X., Li, S., Li, X.-T., & Zhu, H. (2021) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557521666210805104250
Neuroimmunology and Neurological Manifestations of COVID-19
Weissert, R. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.103026
SARS-CoV-2 vaccination management in patients with chronic plaque psoriasis
Bellinato, F., Mazzariol, M., & Gisondi, P. (2022) · doi:10.55788/dfae1d42
Owen, G. R., Evans, C. A., Nair, A., Ross, S. J., Glenister, M. A., Kis, Z., & Dickman, M. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.02.735822
Isono, T., Kojima, A., Nishida, T., Kobayashi, Y., Ishiguro, T., Takaku, Y., Kagiyama, N., & Kurashima, K. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4276-24
Philosophy and the “Framing” of Translational Science
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0002
SARS-CoV-2 anti-N antibodies among healthcare personnel without previous known COVID-19
Tiwary, S. K., O’Neil, C. A., Peacock, K. M., Cass, C., Amor, M., Wallace, M. A., McDonald, D., Arter, O. G., Alvarado, K., Vogt, L. C., et al. (2024) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2024.389
“14,40 Extended follow-up periods also increased the likelihood that HCP would undergo COVID-19 testing, the results of which may have biased their self-assessment of prior symptomatology at follow-up.”
BackgroundHargadon, K. M. (2021) · Journal of Global Health Reports · doi:10.29392/001c.26142
Tagawa, A. (2022) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12721 · Cited by 1
An Overview on the Ongoing Clinical Trials of COVID-19 Vaccines
Fatima, S. K., Rasool, A. T., Sabir, A., et al. (2020) · doi:10.31703/giidr.2020(v-i).05
Molecular mastery: Harnessing DNA technology for disease prevention
Dornadula, G., Ramakrishna, C., Shaik, S. B., Meriga, P. K., Chintha, L., Gurugari, Y., D., K., Shaik, S. F., & Cheong, S. H. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101976
“82 Diagnostics : Production of recombinant probes and enzymes used in molecular diagnostics, including PCR-based detection of pathogens.”
Alavi, M., Mousavi, M., Jazayeri, M., & Ebadifar, A. (2023) · Avicenna Journal of Medical Biotechnology · doi:10.18502/ajmb.v15i4.13501
“They prepare the immune system to identify the virus 13,14 .”
BackgroundPossible Mechanisms of mRNA-LNP Degradation: A Comprehensive Review
Khan, M. F. H., Islam, T., Mishra, A., & Kamen, A. (2026) · Vaccines · doi:10.3390/vaccines14070620 · Cited by 1
“They are considered an innovative approach for immunization and have emerged as a promising alternative to traditional vaccines [1]. mRNA vaccines from Pfizer/BioNTech and Moderna have significantly changed the course of the SARS-CoV-2 pandemic [2,3].”
Development of Machine Learning Model for Vaccination Simulation Tool using Artificial Intelligence
Verma, R. (2023) · International Conference on I-SMAC (IoT in Social, Mobile, Analytics and Cloud) (I-SMAC) · doi:10.1109/i-smac58438.2023.10290601
“The NPIs and the interruptions they cause are anticipated to be used less frequently as the vaccine-based technique progressively takes over [4].”
BackgroundHaberman, R. H., Jaros, B. D., & Scher, J. U. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000813
Tramboo, M. R., Farhana, A., Zahoor, D., Iqbal, I., & Mohuiddin, Z. (2024) · Motaleat-e Tatbiqi-e Honar · doi:10.61186/jommid.12.2.100
Advanced Nanoparticles for Vaccine Development
Dhanya, S. (2026) · Advanced structured materials · doi:10.1007/978-981-92-1034-3_8
Gu, Z., Wang, G.-A., Feng, Z., Sun, C., Li, S., Zhang, K., & Li, H. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01705 · Cited by 1
Guerrero-Araya, E., Ravello, C., Rosemblatt, M. S., et al. (2023) · medRxiv · doi:10.1101/2023.03.27.23287800
Covid-19 and Its Vaccine Development: A Narrative Review
Septinia, R., & Hasmono, D. (2021) · Jurnal Sains dan Kesehatan · doi:10.25026/jsk.v3i6.444 · Cited by 1
“001) against symptomatic COVID-19 in ≥16 years old of participants [70].”
BackgroundDecoy therapeutics for COVID-19 and influenza: principles and translation
Liang, J., Zhang, Z., Xu, Y., Mubareka, S., Rotstein, O. D., & Zhang, H. (2026) · Trends Open · doi:10.1016/j.treopn.2026.07.008
Scholz, L., Hoymann, N., Alboradi, S., Grabar, V., Uehre, G. M., Toth, G., Mészáros, J., Gennari, P., Tchaikovski, S. N., Ignatov, A., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1849532
Bignon, E., Marazzi, M., Grandemange, S., & Monari, A. (2022) · doi:10.1101/2022.01.05.475107 · Cited by 13
Abouzid, I. B., Lotfy, M. M., & Elbestawy, A. R. (2026) · BioMedInformatics · doi:10.3390/biomedinformatics6050085
A Novel SARS-CoV-2-Derived Infectious Vector System
Elfayres, G., Xiao, Y., Pan, Q., Liang, C., Barbeau, B., & Berthoux, L. (2025) · Microbiology Research · doi:10.3390/microbiolres16060125
FDA approval of Pfizer-BioNTech: Evaluating the significance of mRNA vaccine approval
Monawwer, S. A., & Naeem, R. (2021) · Journal of Global Health Economics and Policy · doi:10.52872/001c.30733
Longitudinal and comparative analysis of humoral response upon COVID-19 vaccination
(2021) · doi:10.1101/2021.10.14.21264762
“Several vaccines have been quickly and effectively developed to resolve this pandemic (Baden et al., 2021; Polack et al., 2020; Voysey et al., 2021).”
BackgroundA Comparative Study on Different Approaches of COVID-19 Vaccines
Rahman, M. A., Chayon, R. M., Aziz, A., Faria, F. T. J., Islam, M. A., & Rahman, M. R. (2023) · European Journal of Pharmaceutical Research · doi:10.24018/ejpharma.2023.3.4.58
“Finally, AstraZeneca shows 92% effectiveness in opposition to people who were hospitalized [53] and one dose effectiveness estimated at 60-71% [54] against Delta (B.”
Real-world impact of NVX-CoV2373 COVID-19 vaccine in immunocompromised individuals in South Korea
Gwak, E., Choe, S., Kim, K., Bolormaa, E., Gschwend, M. H., Fix, J., Vadivale, M., Rousculp, M. D., & Choe, Y. J. (2026) · BMC Public Health · doi:10.1186/s12889-026-26592-1 · Cited by 1
“IIC are often excluded from or vastly underrepresented in clinical trials of vaccines, and meta-analyses and systematic reviews of COVID-19 vaccine clinical trials have mostly focused on mRNA-based COVID-19 vaccines [9–12].”
(2021) · doi:10.1101/2021.12.26.21268358
“4 infection and associated infectivity [11,12], and preventing the spread of COVID-19 [9].”
BackgroundInfluentialSuntharasaj, T., Ruangvutilert, P., Sirichotiyakul, S., Komwilaisak, R., Thongphanang, P., & Chirdchim, W. (2024) · The Open COVID Journal · doi:10.2174/0126669587350876241024103135
Madelon, N., Buendía, G. A. R., Rodríguez, P. F., Donati, Y. R. A., Fontannaz, P., Ciancaglini, M., Adouan, W., Arsac, E., Fonta, N., Goldstein, R., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aee4776
Sardinha, D. M., Ferreira, A. L. D. S., Cabral, A. T. M., Macias, B. S. G., de Sá, C. A. F., Alencar, J. L., Almeida, I. D. S. D. S. P. D., Fernandes, N. C., Lima, K. V. B., Guimarães, R. J. D. P. S. E., et al. (2021) · Uniedusul Editora eBooks · doi:10.51324/86010749.10
Development of Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-COV-2) Vaccines
Inaku, K. O., Ene, A. B., Kasimu, S., & Bolarin, D. M. (2022) · Nigerian Journal of Medicine · doi:10.4103/njm.njm_172_21
Proporción de la población con vacunación completa contra Covid-19 a nivel mundial
Pinzón, J. E. D. (2022) · Revista Repertorio de Medicina y Cirugía · doi:10.31260/repertmedcir.01217372.1329
Elbahr, U. S., Erdem, H., Ankaralı, H. Ç., -, C. E. P. D. L. R., PASTRANA, J., Vineeth, C., HEJRES, S., Kaynar, L., ÖZTÜRK, Ç. P., Abalı, H., et al. (2024) · Flora the Journal of Infectious Diseases and Clinical Microbiology · doi:10.5578/flora.202402994
Biton, L., Shvartsur, R., Grinberg, K., Kagan, I., Linetsky, I., Halperin, O., Azab, A. N., & Cohen, O. (2023) · Nursing Inquiry · doi:10.1111/nin.12601
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.